Vc Thoughts, Health, Dna, Rna, Healthcare.
has been calculated that even at $5 million, it would still be cost-effective. This is primarily due to the 15.65 QALYs (over the 5.29 of Spinraza), and the decreased burden to the healthcare system associated with the reduction of “recurrent” patients. In rare diseases, the improvement in the